Faron Pharmaceuticals H2 report: A potential game-changer - Redeye

Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H2 report and clinical progress with lead candidate Bexmarilimab. We make some adjustments to our overall estimates following a revision of our model. Accordingly, as we continue to see a compelling case rooted in an exciting pipeline, we revise our fair value range and raise our base case valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/887741/faron-pharmaceuticals-h2-report-a-potential-game-changer?utm_source=finwire&utm_medium=RSS